Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Advances analyze found that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://aarong653jlm4.yourkwikimage.com/user